消息面上，2月25日，全球第四大锂矿生产国津巴布韦出口政策变动。公开信息显示，津巴布韦矿业部2 月25日宣布立即暂停所有原矿及锂精矿出口（含在途货物），旨在加强矿产监管与问责。未来仅持有效 采矿权及获批选矿厂的企业具备出口资格，禁止代理及第三方贸易商出口。企业申请时需提交省级矿业 办关于选矿能力及合规的建议信，并申报矿物成分。违规者（如续用过期待办）将吊销出口许可乃至采 矿权。此外，瑞银2月5日发布的研报预计，2026年全球碳酸锂市场将呈现供给紧缺格局，并将2026年碳 酸锂价格预期上调至26000美元/吨（按当时汇率为18万元/吨）。瑞银表示，锂市场或迎来第3个价格周 期。（详见此前报道锂市突变！全球第四大生产国：暂停出口） 作者：孟妹 | | | | 盐湖股份 | | C. Q | | | --- | --- | --- | --- | --- | --- | --- | | | | | 000792 融 深股通 | | | | | 39.53 | 今开 | | 37.83 最高 | 39.69 最低 | 37.50 | | | 9.20% 3.33 | 换手 | 2.22% 总手 | | 117万 | ...

Industry Overview - The lithium mining sector is experiencing a significant surge, driven by expectations of a contraction in global lithium supply and a recent stabilization in lithium prices, leading to heightened performance recovery expectations in the industry [2][3] - Zimbabwe, the largest lithium exporter in Africa, has announced a suspension of lithium concentrate and raw ore exports, which is expected to tighten short-term supply and potentially drive lithium prices significantly higher [3] Company Highlights - Erkang Pharmaceutical's subsidiary, Erkang Mining, established in Nigeria, is engaged in lithium exploration and mining, positioning the company to benefit from rising lithium prices [6] - Jinyuan Co. is advancing its lithium salt project and has acquired a 15% stake in Ali Lithium Source to enhance its lithium resource reserves, which will benefit from the industry's improving conditions [6] - Salt Lake Co. has successfully implemented a technology upgrade that has improved lithium recovery rates to 95%, positioning it as a leading domestic player in lithium extraction [6] - Tianqi Lithium's Greenbush lithium spodumene mine in Australia is the largest and highest-grade lithium project currently in production, with an annual capacity of 1.62 million tons, set to benefit from the industry's growth [6] Market Dynamics - The lithium mining and processing sectors are expected to see increased demand for equipment due to expansions in lithium mining projects and new lithium salt production capacities, benefiting companies involved in the manufacturing of lithium mining and processing equipment [5] - The recovery in lithium prices is anticipated to enhance profitability for lithium salt processing companies, especially those with strong cost control and scalable production capabilities [4]

证券日报网讯2月25日，尔康制药（300267）在互动平台回答投资者提问时表示，公司在尼日利亚的孙 公司尔康矿业主要从事锂矿勘探、开采和加工业务，自2024年第四季度建成投产以来，业务稳步发展， 产量持续提升。 ...

经济观察网近期尔康制药（300267）的股票动态主要围绕交易数据和资金面变化。2026年2月12日，融 资融券余额为3.29亿元，较前一日下滑2.55%，其中融资买入591.48万元，融资净卖出860.2万元，显示 短期融资资金流出压力。股价方面，近7天(2026年2月6日至13日)呈现震荡下行趋势，区间跌幅达 13.52%，最新收盘价3.71元(截至2月13日)，较2月6日高点3.85元有所回调；同期成交活跃度波动较大， 2月10日换手率达3.67%，但2月12日降至2.27%。资金流向显示，2月13日主力资金净流入894.8万元，但 大单资金呈净流出，反映市场分歧。 以上内容基于公开资料整理，不构成投资建议。 ...

Group 1 - The core viewpoint of the news is that Erkang Pharmaceutical experienced a significant drop in stock price, with an 8.83% decline on January 30, resulting in a trading volume of 546 million yuan [1] - As of January 30, the financing balance of Erkang Pharmaceutical reached 365 million yuan, accounting for 4.63% of its market capitalization, indicating a high level of financing activity [1] - The company reported a net financing outflow of 14.02 million yuan on January 30, with a total financing buy amount of 37.85 million yuan and a repayment of 51.87 million yuan [1] Group 2 - As of September 30, the number of shareholders of Erkang Pharmaceutical increased by 14.88% to 49,100, while the average circulating shares per person decreased by 12.95% to 28,966 shares [2] - For the period from January to September 2025, Erkang Pharmaceutical achieved a revenue of 1.006 billion yuan, representing a year-on-year growth of 17.81%, and a net profit attributable to shareholders of 39.58 million yuan, up 255.40% year-on-year [2] - The company has distributed a total of 540 million yuan in dividends since its A-share listing, with 61.88 million yuan distributed in the last three years [3]

Group 1 - The A-share market saw a collective decline in lithium mining stocks, with notable drops including Nepean Mining falling nearly 12% and several other companies hitting the daily limit down [1] - The main contract for lithium carbonate experienced a limit down, with a decrease of 11%, currently priced at 148,200 yuan per ton [1] Group 2 - Specific stock performances included Nepean Mining down 11.46% with a market cap of 8.152 billion yuan, and other companies like Meiyuan Co. and Tibet Zhufeng both down 10% [2] - Other significant declines included Western Mining down 9.99% with a market cap of 84.8 billion yuan, and Tianqi Lithium down 8.74% with a market cap of 88.5 billion yuan [2]

Group 1 - The company expects a net profit attributable to shareholders of between -325 million to -385 million yuan for the fiscal year 2025, primarily impacted by asset impairment losses [1] - The company's main business has shown steady growth compared to the same period in 2024, benefiting from the operation of the lithium ore beneficiation plant project in Nigeria, with expected revenue from lithium concentrate business exceeding 200 million yuan [1] - The cash flow from operating activities has significantly increased compared to the same period in 2024, indicating a healthy operational status [1] Group 2 - The company is accelerating its industrial layout in Africa, investing a total of 18 million dollars in comprehensive formulation and injection production projects in Tanzania and Nigeria [2] - The ongoing deepening of China-Africa cooperation provides significant opportunities for Chinese companies to expand overseas, aligning with the company's strategy to enhance its presence in the African renewable energy and healthcare sectors [2] - The company is expected to solidify its long-term development foundation as mining project capacities continue to be released and pharmaceutical manufacturing bases are established, with future performance likely to return to a growth trajectory [2]

Core Viewpoint - The company Erkang Pharmaceutical (300267) expects a significant net loss for 2025, projecting a loss between 325 million to 385 million yuan, compared to a loss of 373.37 million yuan in the same period last year [1]. Financial Performance - The projected net loss for 2025 is estimated to be between 325 million yuan and 385 million yuan [1]. - The previous year's loss was reported at 373.37 million yuan [1].

尔康制药（300267）(300267.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损3.25亿 元至3.85亿元;扣除非经常性损益后的净亏损3.32亿元至3.92亿元。 ...

Core Viewpoint - Erkang Pharmaceutical (300267.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of the listed company between 325 million and 385 million yuan, with a net loss of 332 million to 392 million yuan after deducting non-recurring gains and losses [1] Financial Performance - The company anticipates a net loss of 325 million to 385 million yuan for 2025 [1] - The expected net loss after excluding non-recurring items is projected to be between 332 million and 392 million yuan [1]